Here's Why Exact Sciences (EXAS) is a Strong Momentum Stock

Exact Sciences (EXAS), a molecular diagnostics company, is identified as a strong momentum stock, currently holding a Zacks #1 (Strong Buy) Rank and a 'B' Momentum Style Score. The stock has appreciated 8.3% over the past four weeks, driven by two recent upward revisions to its fiscal 2025 earnings estimates, which increased the Zacks Consensus Estimate by $0.07 to $0.36 per share. This positive momentum is further supported by the company's significant average earnings surprise of +329.9%, positioning EXAS as a notable consideration for investors.

Analysis

Exact Sciences (EXAS), a molecular diagnostics company focused on cancer detection and prevention, currently holds a Zacks #1 (Strong Buy) Rank, indicating a highly favorable investment outlook. This strong fundamental rating is supported by a VGM Score of B, reflecting a balanced profile across value, growth, and momentum characteristics. The company's R&D efforts in colorectal cancer screening, molecular residual disease testing, and multi-cancer screening position it within a critical and growing segment of the healthcare sector.

EXAS has demonstrated significant positive market momentum, with its shares appreciating 8.3% over the past four weeks. This price performance is reinforced by recent analyst activity, as two analysts revised their fiscal 2025 earnings estimates upwards within the last 60 days. Consequently, the Zacks Consensus Estimate for fiscal 2025 increased by $0.07 to $0.36 per share.

The company's historical earnings performance is robust, evidenced by an impressive average earnings surprise of +329.9%. This consistent outperformance, combined with the upward trajectory of analyst estimates and a Momentum Style Score of B, suggests a strong positive outlook for the stock. These factors collectively indicate sustained investor interest and potential for continued share price appreciation.

Key Decisions for Investors

• Investors should consider EXAS for momentum-driven portfolios, given its Zacks #1 (Strong Buy) Rank, B Momentum Style Score, and 8.3% share price appreciation over the past four weeks.
• Monitor future analyst estimate revisions closely, as the recent upward adjustments for fiscal 2025 earnings and a significant average earnings surprise of +329.9% suggest a positive earnings trajectory.
• Evaluate EXAS within the context of the healthcare diagnostics sector, recognizing its specialization in cancer detection and prevention as a key driver in a growing and critical market segment.